[go: up one dir, main page]

EA199800770A1 - Лекарственный препарат для терапевтического лечения вирусного гепатита - Google Patents

Лекарственный препарат для терапевтического лечения вирусного гепатита

Info

Publication number
EA199800770A1
EA199800770A1 EA199800770A EA199800770A EA199800770A1 EA 199800770 A1 EA199800770 A1 EA 199800770A1 EA 199800770 A EA199800770 A EA 199800770A EA 199800770 A EA199800770 A EA 199800770A EA 199800770 A1 EA199800770 A1 EA 199800770A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viral hepatitis
drugs
therapeutic treatment
neoplasia
interferon
Prior art date
Application number
EA199800770A
Other languages
English (en)
Other versions
EA001147B1 (ru
Inventor
Джулио Тарро
Ренцо Броццо
Original Assignee
ИФИ ИСТИТУТО ФАРМАКОТЕРАПИКО ИТАЛИАНО С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT96RM000136 external-priority patent/IT1283945B1/it
Priority claimed from ITRM960427 external-priority patent/IT1284852B1/it
Application filed by ИФИ ИСТИТУТО ФАРМАКОТЕРАПИКО ИТАЛИАНО С.п.А. filed Critical ИФИ ИСТИТУТО ФАРМАКОТЕРАПИКО ИТАЛИАНО С.п.А.
Publication of EA199800770A1 publication Critical patent/EA199800770A1/ru
Publication of EA001147B1 publication Critical patent/EA001147B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описано использование природного α-интерферона человека для изготовления лекарственного препарата в жидкой форме в целях перорального введения этого препарата в дозах, составляющих 100 - 500 ед./день, для терапевтического лечения вирусных инфекций, в частности вирусного гепатита, опухолевых и иммунных заболеваний у человека и животных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800770A 1996-02-28 1997-02-27 Лекарственный препарат для терапевтического лечения вирусного гепатита EA001147B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96RM000136 IT1283945B1 (it) 1996-02-28 1996-02-28 Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
ITRM960427 IT1284852B1 (it) 1996-06-14 1996-06-14 Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
PCT/IT1997/000040 WO1997031649A1 (en) 1996-02-28 1997-02-27 PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON

Publications (2)

Publication Number Publication Date
EA199800770A1 true EA199800770A1 (ru) 1999-02-25
EA001147B1 EA001147B1 (ru) 2000-10-30

Family

ID=26332096

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800770A EA001147B1 (ru) 1996-02-28 1997-02-27 Лекарственный препарат для терапевтического лечения вирусного гепатита

Country Status (14)

Country Link
US (1) US6884411B1 (ru)
EP (1) EP0886527B1 (ru)
JP (1) JP2000506839A (ru)
KR (1) KR100394382B1 (ru)
AT (1) ATE205397T1 (ru)
AU (1) AU722987B2 (ru)
BR (1) BR9707772A (ru)
DE (1) DE69706657T2 (ru)
DK (1) DK0886527T3 (ru)
EA (1) EA001147B1 (ru)
ES (1) ES2160927T3 (ru)
GE (1) GEP20012489B (ru)
PT (1) PT886527E (ru)
WO (1) WO1997031649A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2129011C1 (ru) * 1998-04-09 1999-04-20 Григорян Седа Суреновна Способ интерферониндуцирующей или интерферонактивированной терапии и средство для его осуществления
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
ITMI20030826A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente interferone per il
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
TW224053B (ru) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use

Also Published As

Publication number Publication date
EP0886527A1 (en) 1998-12-30
WO1997031649A1 (en) 1997-09-04
KR19990082559A (ko) 1999-11-25
BR9707772A (pt) 2000-01-04
DK0886527T3 (da) 2002-03-04
US6884411B1 (en) 2005-04-26
AU2229997A (en) 1997-09-16
ATE205397T1 (de) 2001-09-15
EA001147B1 (ru) 2000-10-30
DE69706657D1 (de) 2001-10-18
ES2160927T3 (es) 2001-11-16
PT886527E (pt) 2001-12-28
EP0886527B1 (en) 2001-09-12
DE69706657T2 (de) 2002-06-20
JP2000506839A (ja) 2000-06-06
GEP20012489B (en) 2001-07-25
KR100394382B1 (ko) 2004-02-05
AU722987B2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
DK0911033T3 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
FI884013A0 (fi) Konjugat av cytokiner med immunoglobuliner.
NO306377B1 (no) Doseform for avgivelse av et medikament
DK0502092T3 (da) Oralt præparat til behandling af inflammatoriske tarmsygdomme
GR3025502T3 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
MD990258A (en) Method of treatment of the acute viral hepatitis B
BR0108997A (pt) Terapia imune adjuvante para hiv
DK0559145T3 (da) Lægemiddel til truende abort
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
Learned Directions for HIV research
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
张闿珍 et al. MALIGNANT EXOPHTHALMOS A CLINICAL OBSERVATION OF 12 CASES
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
RU92011195A (ru) Способ уменьшения дозы химиопрепаратов, используемых для лечения инфекционных заболеваний при одновременном повышении их терапевтической эффективности
RU94016144A (ru) Средство для лечения больных болезнью рейтера

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU